Septerna, Inc.

SEPN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023
Revenue $46.0M $1.1M $151.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $97.6M $65.3M $36.0M
SG&A Expense $29.2M $16.6M $9.7M
Operating Income $-68.3M $-80.8M $2.1M
Operating Margin -148.6% -7,518.4% 1,374.2%
Interest Expense
Pretax Income $-48.9M $-72.3M $-48.9M
Income Tax Expense $12.0K $-498.0K $691.0K
Net Income $-48.9M $-71.8M $4.2M
Net Margin -106.4% -6,678.9% 2,768.2%
EPS (Basic) $-1.10 $-1.82 $0.01
EPS (Diluted) $-1.10 $-1.82 $0.01
Shares Outstanding (Basic) 44.9M 44.3M 39.6M 38.6M
Shares Outstanding (Diluted) 44.9M 44.3M 39.6M 43.5M
Dividends Per Share